Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal® [Yahoo! Finance]
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
FREMONT, Calif., March 12, 2026 BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology . The article, " The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease ," showed that ultrasensitive molecular residual disease (MRD) testing with NeXT Personal can perform better than current standard approaches in predicting patient outcomes following neoadjuvant therapy (NAT). The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading US cancer centers. The results demonstrate the ability of NeXT Personal to provide a more precise risk-stratification for patients who have received NAT. A key finding of the study was the necessity of the ultrasensitive range for accurately tra
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 [Yahoo! Finance]Yahoo! Finance
- Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption [Yahoo! Finance]Yahoo! Finance
- Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD AdoptionBusiness Wire
- Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®Business Wire
- Personalis (PSNL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PSNL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "holMarketBeat
PSNL
Earnings
- 2/26/26 - Beat
PSNL
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- PSNL's page on the SEC website